

MEETING OF THE UK KIDNEY RESEARCH CONSORTIUM

15 July 2011 London

Report

Present:

Bruce Hendry (chair)

Neil Turner

Phil Kalra

Charles Kernahan

David Wheeler

Paul Cockwell

Ken Farrington

Iain Macdougall

Fiona Karet

Liz Lightstone

Martin Wilkie

Donald Fraser

Edmund Lamb

Richard Cornall

Michael Nation

Ramaswamy Diwakar

Daniel Zehnder

Rob Lewis

Donal O'Donoghue

Introduction

The chair gave an introduction and description of the UKKRC. The UKKRC was described as follows:

- An inclusive clinical research grouping
- Co-sponsored by KRUK and UKRA
- Rotating chair
- Organised as Clinical Study Groups (CSG)
- Concerned with the ideas, planning, funding, initiation and delivery of renal clinical research
- Works closely with NIHR (and equivalents)
- Role is facilitation not regulation

Approval of a new CSG in Renal Anaemia, chaired by Iain Macdougall, was announced.

Clinical Study Groups

CSG reports in person were made by

David Wheeler on CKD-MBD

Phil Kalra on CVD

Ken Farrington on HD (and covered the PD group of Simon Davies)

Fional Karet on genetics

Paul Cockwell on CKD

Iain Macdougall on Renal Anaemia

The chair gave brief reports on behalf of the leads of the following CSG.

Transplantation (Paul Harden)

Cystic Diseases (Albert Ong)

GN/Vasculitis (Lorraine Harper)

Discussion of the AKI and paediatric CSGs was deferred to the next UKKRC meeting.

The reports provided by CSG leads will be provided for information in an Appendix.

The CSG reports were very strong evidence of an increasing programme of renal clinical science in the UK. The progress over the last 12-18 month was striking. A range of studies are funded and ongoing. A further group of strong studies are close to funding success and more ideas are in development.

National Priorities for renal clinical research

The chair, Donal O'Donoghue and Phil Kalra introduced a debate on the strong possibilities of significant National funding for high quality renal clinical research. Donal reported on a meeting with Sally Davies and Phil briefed the group about a letter from the NIHR-HTA. A small number of strong bids for funding were well placed to succeed. The HTA panel are looking to receive suggested "research questions" that will be discussed for development of funding calls.

The UKKRC group were encouraged to discuss the 1-2 best areas for full UKKRC national support. It was agreed that patient benefit within 3-5 years was an important criterion for judging these projects. After a stimulating and open discussion the group reached a consensus of strong support for the following:

Phosphate control and cardiovascular outcomes in CKD3-5D (lead David Wheeler)

CKD progression studies (e.g. bicarbonate, ACEi/ARB withdrawal) (lead Paul Cockwell)

David Wheeler and Paul Cockwell undertook to take these forward putting together strong teams in support. The UKKRC will work to achieve a wide consensus of national support for these bids for HTA-NIHR funding.

There is scope for success with further strong bids for funding and these were discussed also. These areas will be examined by CSG leads.

Date of Next meeting

This will be coordinated with the NIHR renal specialty CCRN group and will be held **in London, 9th December 2011**

Bruce Hendry